4.6 Review

M1 muscarinic acetylcholine receptor in Alzheimer's disease

期刊

NEUROSCIENCE BULLETIN
卷 30, 期 2, 页码 295-307

出版社

SPRINGER
DOI: 10.1007/s12264-013-1406-z

关键词

agonist; Alzheimer's disease; amyloid; cholinergic hypofunction; M1 muscarinic acetylcholine receptor; tau

资金

  1. National Institutes of Health, USA [R01AG038710, R01AG021173, R01AG044420, R01NS046673]
  2. Alzheimer's Association
  3. National Natural Science Foundation of China [91332112, 81225008, 81161120496]
  4. Fundamental Research Funds for the Central Universities of China
  5. Fok Ying Tung Education Foundation

向作者/读者索取更多资源

The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer's disease (AD). Muscarinic acetylcholine receptors (mAChRs) mediate acetylcholine-induced neurotransmission and five mAChR subtypes (M1-M5) have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists for AD treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据